New peptide serum takes on hair loss in head-to-head trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants aged ≥18 years. * Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females. * Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire). * Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study. * Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit. * Able to attend all scheduled visits during the 24-week study period. Exclusion Criteria: * Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia). * History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma. * Psychiatric disorders or other conditions that may affect participant safety or compliance. * Pregnant or breastfeeding women. Hair and scalp-related exclusions: * Diffuse hair thinning involving the occipital area. * Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis). * History of hair transplantation at any time or hair extensions within 6 months prior to screening. * Use of cosmetic products for hair loss concealment within 2 weeks prior to screening. * Use of light/laser therapy on the scalp within 3 months prior to screening. * Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening. * Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening. * Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening. Medication-related exclusions: * Known hypersensitivity to study-related products or ingredients. * Use of dutasteride within 12 months prior to screening. * Use of systemic cytotoxic agents. * Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp). * Use within 6 months prior to screening of: * Minoxidil (topical or oral) * Finasteride (topical or oral) * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide) * Prostaglandin analogs applied to the scalp * Estrogen or progesterone topical preparations * Tamoxifen * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin) * Drugs associated with hair loss (e.g., valproic acid) * Participation in another clinical trial within 1 month prior to screening or during this study.